Dupixent COPD denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Dupixent for COPD as Duplicate Therapy

A duplicate-therapy denial means UnitedHealthcare's system flagged that you are already receiving a medication it considers to overlap functionally with Dupixent (dupilumab). In the context of COPD, this typically arises when a patient is already using an inhaled corticosteroid-containing regimen or another biologic, and the plan's clinical criteria require that Dupixent provide a meaningfully distinct therapeutic role rather than layer on top of an equivalent agent.

This denial is appealable. Dupilumab targets a specific inflammatory pathway (type 2 / eosinophilic inflammation driven by IL-4 and IL-13 signaling) that is mechanistically distinct from bronchodilators, inhaled corticosteroids acting locally in the airway, or other biologics that block different cytokine pathways. Your prescriber's documentation should make that mechanistic distinction explicit.

## Federal Appeal Rights

You have strong federal protections:

• ERISA §503 (employer-sponsored plans) guarantees a full-and-fair internal review with a written denial reason.
• ACA §2719 entitles you to an independent external review by an accredited Independent Review Organization (IRO) — at no cost to you — if the internal appeal is denied.
• You generally have 180 days from the denial notice to file an internal appeal, and the external review request window is typically 4 months from the final internal denial.
• An expedited review (72-hour turnaround) is available when your condition is urgent or the standard timeline could seriously jeopardize your health.

## What to Gather

1. Diagnosis documentation — chart notes confirming COPD diagnosis, spirometry results, exacerbation history, and eosinophil or type-2 inflammatory profile from your medical record. 2. Current medication list with dates — show every inhaled and systemic therapy you are on, the start dates, and the distinct mechanism or indication for each. 3. Prescriber medical-necessity letter — your physician should explain (a) the specific type-2 inflammatory endotype driving your COPD, (b) why existing therapies do not address that pathway adequately, and (c) why Dupixent is not duplicative but additive in a clinically meaningful way. 4. FDA-approved prescribing label — reference the approved indication language and the mechanism of action section to show the distinct biological target. 5. UHC's own coverage policy — request or download UnitedHealthcare's current medical policy for dupilumab. Map each "not duplicate" criterion to a specific chart fact.

## Criteria-Mapping Structure

In your appeal letter, reproduce each criterion from UHC's policy and the prescribing label, then answer each with a dated chart entry:

| Policy/Label Requirement | Supporting Chart Fact | |---|---| | Distinct mechanism from current therapy | [Prescriber note citing IL-4/IL-13 pathway not covered by existing regimen] | | Type-2 inflammatory phenotype confirmed | [Lab or clinical documentation in chart] | | Current regimen inadequate for that endotype | [Exacerbation records / symptom burden notes] |

Keep copies of every submission and document receipt dates. If UHC denies the internal appeal, file the external IRO request promptly — IRO decisions are binding on the insurer.